Check 35,000+ stocks against 26 valuation models and 37 quality factors

WuXi AppTec Co Ltd H (2359) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of WuXi AppTec Co Ltd H HK$229, price HK$208, upside +10.2%, quality 75 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? Yes
Good quality? Yes
Add to watchlist

Healthcare · HK · Home China · ISIN CNE100003F19

WA Broad data Sep 24, 2026

WuXi AppTec Co Ltd H

2359 · HK

Quality WatchlistQuality growthA strong company, but the current price is close to Fair Value.

·Fair value HK$228.80 · Fairly valued (+10%)

✓Quality 75/100

✓Healthy Growth (revenue 5y +22.4 %/yr)

✓Highly profitable · 43.6% net margin (TTM)

✓Low debt · generates free cash flow

·0.93% dividend yield

✓Ranks above peers (10/14)

✓Wide moat 93/100

!The models disagree: range HK$126.19 to HK$456.89

!Weak on dividend: 19 out of 100

26 models, one by oneBear HK$126.19 to bull HK$456.89 Growth analysisrevenue history, year by year Quality 75/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch WuXi AppTec Co Ltd H for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range HK$26.71 – HK$208.00 · fair‑value band HK$126.19 – HK$456.89 · the HK$207.60 price screens below the HK$228.80 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow WuXi AppTec Co Ltd H in your weekly email

Every Wednesday you see whether WuXi AppTec Co Ltd H is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People's Republic of China, the United States, Europe, and internationally. The company operates through WuXi Chemistry, WuXi Testing, WuXi Biology, and Others segments. It offers contract research, development, and manufacturing organization (CDRMO) services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions which support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides laboratory testing services, such as toxicology, DMPK, and bioanalytical services; clinical contract research organization services, including Phase I to Phase IV clinical development services, and bioequivalence for products including pharmaceuticals and biologics; and site management organization, patient recruitment, site start-up, and academic research organization. In addition, it offers services for biology; CDRMO platform for small molecules, oligonucleotides, and peptides; drug research and development testing; and clinical research services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.

Stock analysis

WuXi AppTec Co Ltd H (2359) currently trades at HK$207.60, while our model-based Fair Value estimate is HK$228.80, implying the stock looks roughly 9.3% undervalued today.

Valuation

Bull case: the Growth Earnings group reads highest at a median of HK$206.42 per share, and 4 of the 26 models we run sit above the HK$207.60 price.

Bear case: the Dividend Discount group reads lowest at HK$29.50, and 22 of the 26 models stay below the price. Evidence for this calculation is high.

Scenario range: HK$126.19 (bear) to HK$456.89 (bull), the price of HK$207.60 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 75/100 (high quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

WuXi AppTec Co Ltd H reported revenue of 45.5B CNY in FY2025 versus 22.9B CNY in FY2021, a compound +18.7%/yr. Reported net income was 19.2B CNY in FY2025, compounding +39.2%/yr from FY2021.

Key figures

Market cap HK$601B (≈ $76.7B) · P/E ratio 19.1 · P/S ratio 8.06 · EPS (TTM) HK$6.97 · Dividend yield 0.9% · Net margin 42.1% · Return on equity 25.7% · Return on assets (EBIT) 14.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

What moves the price

The share trades at its 52-week high and 116% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −6% fair-value upside, at 10%, 2359 screens cheaper than that median.

Fair Value models

Bear HK$126.19 Fair Value HK$228.80 Bull HK$456.89

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (HK$3.69 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

FCF DCF HK$84.78 HK$129.66 HK$276.41 75

EPV HK$54.41 HK$61.98 HK$68.71 74

Growth DCF HK$80.57 HK$145.13 HK$281.22 74

All 26 models by family

DCF Models

FCF DCF HK$84.78 HK$129.66 HK$276.41 75

Owner Earnings HK$110.92 HK$244.45 HK$537.30 70

5Y Revenue Exit HK$57.11 HK$89.26 HK$154.60 70

5Y EBITDA Exit HK$86.53 HK$150.07 HK$271.94 72

5Y P/E Exit HK$112.88 HK$243.82 HK$420.89 68

10Y Revenue Exit HK$63.58 HK$117.23 HK$157.80 66

10Y EBITDA Exit HK$86.81 HK$179.52 HK$353.23 64

10Y P/E Exit HK$106.26 HK$235.30 HK$466.15 60

Earnings-Based

Graham-Dodd HK$44.95 HK$313.46 HK$439.90 63

Lynch FV HK$108.55 HK$155.07 HK$201.59 61

PEG = 1.0 HK$108.55 HK$155.07 HK$201.59 57

EPV HK$54.41 HK$61.98 HK$68.71 74

Dividend Discount

Gordon GGM HK$16.50 HK$36.01 HK$60.59 65

DDM Multi-Stage HK$16.50 HK$29.50 HK$37.53 66

Multiples

P/E Multiple HK$109.06 HK$145.42 HK$181.77 63

P/S Multiple HK$41.19 HK$54.91 HK$68.64 58

P/B Multiple HK$84.28 HK$112.37 HK$140.46 55

EV/EBIT HK$86.33 HK$111.28 HK$136.22 66

EV/EBITDA HK$85.72 HK$110.46 HK$135.20 67

EV/Revenue HK$44.45 HK$58.57 HK$72.69 54

Asset-Based

NCAV (Graham) HK$13.76 HK$18.43 HK$27.51 54

Growth DCF

Growth DCF HK$80.57 HK$145.13 HK$281.22 74

Rev-Margin DCF HK$57.11 HK$100.50 HK$170.62 70

Economic Profit

Residual Income HK$47.25 HK$64.48 HK$402.70 64

ROIC Compounder HK$67.09 HK$95.33 HK$136.35 71

Growth Earnings

Growth-Adj P/E HK$144.49 HK$206.42 HK$268.34 67

Open the full fair value analysis →

Notify me when 2359 reaches fair value

Put 2359 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 75/100

Of which business quality 73 · Market factors (momentum, volatility) 90

Profitability 69

Margins and returns on capital today

Quality Growth 79

Are margins and returns improving?

Cashflow 70

Earnings quality: real cash, not paper profit

Fin. Strength 99

Balance sheet, leverage, solvency risk

Investment 20

Disciplined investing over empire-building

Low Volatility 67

Calm price path (market factor)

Momentum 100

Price trend over the last 3–12 months (market factor)

52W Momentum 100

Distance to the 52-week high (market factor)

Net Issuance 79

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 100/100

Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Revenue growth 1 year

+15.8%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+4.9%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+22.4%

Start year 2020 (pandemic). Over 10 years: +25.0% a year

Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+24.3%

’14

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.

+40.7%

Earnings growth per share plus dividend.

Earnings per share, growth per year+39.8%

Dividend (yield on the price)0.9%

Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.46% vs 41%, picking up

Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.21% → 37%

2025 sits 104% above its own trend. The rate follows the median trend of the last 5 years, not that single year.

Start year 2020 (pandemic)

Growth Forecast

A lot of optimism in the price

The price assumes about as much growth as the company has delivered so far and more than analysts expect.

What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).

+21.3%

Yearly growth needed for the next five years to justify today's price.

What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.

+14.9%

Yearly sales growth analysts expect, extended to five years.

After inflation (Hong Kong: IMF forecast 2.1% a year to 2030, 1.8% from 2016 to 2025) that is about +18.8% a year for the price and +12.5% for the forecasts.

Forecast 2026 (sales)+18.4%

Forecast 2027 (sales)+16.9%

Projected 2028 (sales)+15.0%

Projected 2029 (sales)+13.2%

Projected 2030 (sales)+11.3%

Watch 2359, get fair value alerts →

Recent news

News mood ⓘNews mood, the average tone of recent news (86 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive

Recent news coverage is more positive than average.

Capitalize on Pharmacokinetics Outsourcing Disruption as Charles River, Labcorp, WuXi AppTec, Eurofins and Sygnature Compete to Dominate Dru Yahoo Finance · Sep 23, 2026
Capitalize on the In Vivo Toxicology Shake-Up: Benchmark Charles River, Labcorp, Evotec, WuXi AppTec and Thermo Fisher Before R&D Shifts Yahoo Finance · Sep 23, 2026
Capitalize on the Drug Discovery Outsourcing Shift: Benchmark Charles River, WuXi AppTec, Evotec, Labcorp and Sygnature to Secure R&D RO Yahoo Finance · Sep 23, 2026
Capitalize on the Toxicology Testing Services Market Shift: Benchmark Labcorp, Charles River, Eurofins, SGS and WuXi AppTec to Secure Growth Yahoo Finance · Sep 23, 2026

Compare WuXi AppTec Co Ltd H with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Diagnostics & Research · 142 stocks

Beats the industry median on 10/14 measures

Overall it ranks above its industry peers.

Valuation

Quality Score 75 · Top 25%

Fair Value upside +10% · Top 25%

Profitability

Return on equity (TTM) 26% · Top 25%

Return on assets 12% · Top 25%

Net margin (TTM) 44% · Top 25%

Operating margin (TTM) 41% · Top 25%

Growth and dividend

Revenue growth 29% · Top 25%

Dividend yield (TTM) 0.9% · Below median

Balance sheet

Debt / equity 0.02× · Below median

Valuation Multiplesvs Diagnostics & Research median · lower = cheaper

P/E (TTM) 19.1× · Cheapest 25%

P/B 7.56× · Priciest 25%

P/S (TTM) 13.04× · Priciest 25%

P/FCF 6.6× · Cheaper than median

EV/EBITDA 26.1× · Priciest 25%

Strength profile in five axes (Snowflake)

This stock

Sector peers

VALUE (fair-value potential)47 · sector 0

FUTURE (revenue growth)100 · sector 24

PAST (return on equity)100 · sector 8

HEALTH (low debt)99 · sector 96

DIVIDEND (yield)19 · sector 29

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
Thermo Fisher Scientific Inc TMO	$658.52	$682.58	+4%
Danaher Corporation DHR	$221.09	$207.76	−6%
Lonza Group LONN	CHF 562.80	CHF 151.69	−73%
IDEXX Laboratories, Inc IDXX	$521.50	$495.84	−5%
Agilent Technologies, Inc A	$167.26	$63.90	−62%
Waters Corporation WAT	$425.74	$106.31	−75%
IQVIA Holdings IQV	$270.09	$295.80	+10%
Illumina, Inc ILMN	$247.46	$272.21	+10%
Mettler-Toledo International Inc MTD	$1,491	$635.75	−57%
Quest Diagnostics Incorporated DGX	$234.76	$170.74	−27%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

WuXi AppTec Co Ltd H · Fair Value
HK$228.80 +9%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/2359" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">WuXi AppTec Co Ltd H · Fair Value</span><br><b style="font-size:20px">HK$228.80</b> <span style="color:var(--fvc-g-mitte);font-weight:700;font-size:14px">+9%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "WuXi AppTec Co Ltd H Fair Value". https://www.fairvalue-calculator.com/stock/2359

Frequently asked questions

Is WuXi AppTec Co Ltd H (2359) overvalued or undervalued?

As of Sep 24, 2026, our model estimates a fair value of HK$228.80 versus a price of HK$207.60, about +10% upside (undervalued).

What is the fair value of 2359?

Our model-based fair value for WuXi AppTec Co Ltd H is HK$228.80 (as of Sep 24, 2026), built from audited fundamentals. The current price: HK$207.60.

What is the quality score of 2359?

WuXi AppTec Co Ltd H has a Quality Score of 75/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for WuXi AppTec Co Ltd H (2359)?

Our model-based price target is the fair value of HK$228.80 (as of Sep 24, 2026) from 26 valuation models. Cautious scenario HK$126.19, optimistic scenario HK$456.89. It is a calculation from audited fundamentals, not an analyst target.

What is the WuXi AppTec Co Ltd H stock forecast for 2026?

Our models put fair value at HK$228.80, about +10% upside versus a price of HK$207.60 (undervalued). Cautious scenario HK$126.19, optimistic scenario HK$456.89. The calculation is refreshed regularly with new filings.

What is the revenue of WuXi AppTec Co Ltd H (2359)?

WuXi AppTec Co Ltd H reported trailing-twelve-month revenue of about HK$46.2B (latest available figure, as of Sep 24, 2026).

Does WuXi AppTec Co Ltd H pay a dividend?

WuXi AppTec Co Ltd H currently shows a dividend yield of about 0.93% relative to its recent price (as of Sep 24, 2026).

What growth is priced into WuXi AppTec Co Ltd H (2359)?

For today's price to be fair in a discounted-cash-flow model, WuXi AppTec Co Ltd H would have to grow free cash flow by +21.3 % per year for five years (discount rate 8.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +22.4 % per year. As of Sep 24, 2026.

What discount rate (WACC) does the fair value of 2359 use?

Our models discount WuXi AppTec Co Ltd H at 8.1 %: a base by market capitalisation (mega), damped by beta 0.49, country premium for Hong Kong. The same rate applies in all 26 models.

What is a reverse DCF?

A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For WuXi AppTec Co Ltd H that is +21.3 % per year a year over ten years, using the same discount rate (8.1 %) and the same formula as our fair value.

How much growth has WuXi AppTec Co Ltd H (2359) delivered so far?

Over the past 5 years revenue at WuXi AppTec Co Ltd H grew +22.4 % a year. The price currently implies +21.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.

How fast is the sector of WuXi AppTec Co Ltd H (2359) growing?

The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into WuXi AppTec Co Ltd H (+21.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.

What is the free cash flow yield of WuXi AppTec Co Ltd H (2359)?

The free-cash-flow yield on the price is 1.94 %: that much free cash flow WuXi AppTec Co Ltd H produces per unit of market value. When it exceeds the discount rate of our models (8.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.

What is the intrinsic value of WuXi AppTec Co Ltd H (2359)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For WuXi AppTec Co Ltd H it is HK$228.80 per share (as of Sep 24, 2026), against a price of HK$207.60. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).

Is WuXi AppTec Co Ltd H stock overvalued or undervalued in 2026?

As of Sep 24, 2026, 2359 trades below its calculated fair value: price HK$207.60, fair value HK$228.80, a gap of about +10% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of 2359?

No. The price is what the market pays today (HK$207.60); the fair value is what the company's own numbers justify (HK$228.80). For WuXi AppTec Co Ltd H the two are HK$21.20 per share apart. That gap is exactly why we show both numbers side by side.

How much is WuXi AppTec Co Ltd H worth?

The market values WuXi AppTec Co Ltd H at about HK$601B (market capitalisation, as of Sep 24, 2026). Per share that is HK$207.60; our models calculate a fair value of HK$228.80 per share.

What do the bullish and bearish scenarios say about 2359?

Our models span a range for WuXi AppTec Co Ltd H: cautious scenario HK$126.19, base HK$228.80, optimistic HK$456.89 per share (as of Sep 24, 2026, price HK$207.60). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of 2359?

WuXi AppTec Co Ltd H trades at a price-to-earnings ratio of 19.1 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$228.80 is built from several models across several years. Other multiples: P/B 7.6, P/S 13.0, EV/EBITDA 26.1.

How solid is the balance sheet of WuXi AppTec Co Ltd H (2359)?

Balance-sheet figures for WuXi AppTec Co Ltd H (as of Sep 24, 2026): return on equity 25.7%, debt of 0.02 per unit of equity. They feed the Quality Score of 75/100, which measures business quality independently of the share price.

How far is 2359 from its 52-week high?

WuXi AppTec Co Ltd H trades at HK$207.60, at its 52-week high of HK$208.00 and 116% above the low of HK$96.13 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of HK$228.80 is for.

Which stocks are comparable to WuXi AppTec Co Ltd H?

From the same area (Healthcare) we also value Thermo Fisher Scientific Inc, Danaher Corporation, Lonza Group, IDEXX Laboratories, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is WuXi AppTec Co Ltd H stock attractive at the current price?

The data as of Sep 24, 2026: price HK$207.60, calculated fair value HK$228.80 (+10%), Quality Score 75/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of 2359 calculated?

We run WuXi AppTec Co Ltd H through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$228.80, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.1 % above its aggregate fair value. WuXi AppTec Co Ltd H currently trades 10 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of WuXi AppTec Co Ltd H (2359)?

The closing price on Sep 23, 2026 was HK$207.60. Our model-based fair value is HK$228.80, about +10% upside (undervalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with WuXi AppTec Co Ltd H right now?

The model range is unusually wide (HK$126.19 to HK$456.89). The outcome hinges heavily on assumptions, so read the point estimate with caution. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.

Where does the earnings growth of WuXi AppTec Co Ltd H (2359) come from?

Earnings per share at WuXi AppTec Co Ltd H grew +35.6 % a year from 2014 to 2025. Broken into its drivers: revenue per share +22.0 %, EBIT margin +5.9 %, tax rate +0.7 %, residual (interest, one-offs) +4.3 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of WuXi AppTec Co Ltd H

How large is the market capitalisation of WuXi AppTec Co Ltd H (2359)?

The market capitalisation of WuXi AppTec Co Ltd H is HK$601B (≈ $76.7B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of WuXi AppTec Co Ltd H (2359)?

The price-to-sales ratio of WuXi AppTec Co Ltd H is 8.06 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of WuXi AppTec Co Ltd H (2359)?

Earnings per share at WuXi AppTec Co Ltd H are HK$6.97 (price ÷ EPS = P/E 19.1). Earnings per share over the last twelve months: total profit spread across every single share.

What is the dividend yield of WuXi AppTec Co Ltd H (2359)?

The dividend yield of WuXi AppTec Co Ltd H is 0.9% (payout 27.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.

What is the net margin of WuXi AppTec Co Ltd H (2359)?

The net margin of WuXi AppTec Co Ltd H is 42.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of WuXi AppTec Co Ltd H (2359)?

The return on equity (ROE) of WuXi AppTec Co Ltd H is 25.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of WuXi AppTec Co Ltd H (2359)?

On an EBIT basis the return on assets of WuXi AppTec Co Ltd H is 14.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of WuXi AppTec Co Ltd H (2359)?

The operating margin of WuXi AppTec Co Ltd H is 40.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at WuXi AppTec Co Ltd H (2359)?

Revenue at WuXi AppTec Co Ltd H is growing +28.8% versus a year earlier (3y avg +4.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at WuXi AppTec Co Ltd H (2359)?

Earnings per share at WuXi AppTec Co Ltd H are growing +23.4% versus a year earlier. How much earnings per share grew versus a year earlier.

How much net cash does WuXi AppTec Co Ltd H (2359) hold?

WuXi AppTec Co Ltd H holds more cash than debt, HK$26.9B net (fiscal year 2025). The company holds more cash than debt, a safety cushion.

Free · no account needed

Watch WuXi AppTec Co Ltd H in the live analysis

One click puts WuXi AppTec Co Ltd H on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.